Drug General Information |
Drug ID |
D0S7UU
|
Former ID |
DIB000384
|
Drug Name |
PF-06260414
|
Indication |
Cachexia [ICD9: 799.4; ICD10:R64]
|
Discontinued in Phase 1 |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Target and Pathway |
Target(s) |
Androgen receptor |
Target Info |
Modulator |
[2]
|
KEGG Pathway
|
Oocyte meiosis
|
Pathways in cancer
|
Prostate cancer
|
NetPath Pathway
|
EGFR1 Signaling Pathway
|
AndrogenReceptor Signaling Pathway
|
FSH Signaling Pathway
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
Coregulation of Androgen receptor activity
|
Regulation of Androgen receptor activity
|
Nongenotropic Androgen signaling
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
FOXA1 transcription factor network
|
Notch-mediated HES/HEY network
|
Reactome
|
Nuclear Receptor transcription pathway
|
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
|
WikiPathways
|
SIDS Susceptibility Pathways
|
Integrated Pancreatic Cancer Pathway
|
Prostate Cancer
|
Integrated Breast Cancer Pathway
|
Nuclear Receptors
|
Androgen receptor signaling pathway
|
References |
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040072) |
---|
REF 2 | Phase I clinical trail of PF-06260414 for treating cachexia. Pfizer Inc. |